114 related articles for article (PubMed ID: 20093522)
1. Resected colorectal cancer among Medicare beneficiaries:adoption of FDG PET.
Zafar HM; Mahmoud NN; Mitra N; Wirtalla C; Armstrong K; Groeneveld PW
Radiology; 2010 Feb; 254(2):501-8. PubMed ID: 20093522
[TBL] [Abstract][Full Text] [Related]
2. Predictors of initial 18F-fluorodeoxyglucose-positron emission tomography indication among patients with colorectal cancer.
Zafar HM; Kramer S; Bonaccorsi D; Langlotz CP; Armstrong K
Nucl Med Commun; 2012 Jul; 33(7):739-46. PubMed ID: 22531828
[TBL] [Abstract][Full Text] [Related]
3. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
Radiology; 2013 Jun; 267(3):807-17. PubMed ID: 23418003
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.
Veenstra CM; Vachani A; Ciunci CA; Zafar HM; Epstein AJ; Paulson EC
J Am Coll Radiol; 2016 May; 13(5):491-6. PubMed ID: 26774883
[TBL] [Abstract][Full Text] [Related]
5. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Features of Second Primary Colorectal Cancer Incidentally Identified by 18F-FDG-PET.
Fujii T; Suto T; Kigure W; Morita H; Katoh T; Yajima R; Tsutsumi S; Asao T; Kuwano H
Hepatogastroenterology; 2015 May; 62(139):599-601. PubMed ID: 26897936
[TBL] [Abstract][Full Text] [Related]
7. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
9. Medicare coverage of PET for cervical cancer.
Carey BP; Coleman RE; Grigsby PW; Siegel BA
J Am Coll Radiol; 2006 Jan; 3(1):19-22. PubMed ID: 17412001
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
11. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
12. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
J Magn Reson Imaging; 2009 Feb; 29(2):336-40. PubMed ID: 19161185
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
14. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
Tatsumi M; Cohade C; Nakamoto Y; Fishman EK; Wahl RL
Radiology; 2005 Dec; 237(3):1038-45. PubMed ID: 16304117
[TBL] [Abstract][Full Text] [Related]
16. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
[TBL] [Abstract][Full Text] [Related]
17. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
19. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination.
Nakamoto Y; Cohade C; Tatsumi M; Hammoud D; Wahl RL
Radiology; 2005 Nov; 237(2):627-34. PubMed ID: 16244271
[TBL] [Abstract][Full Text] [Related]
20. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
